GKOS

GKOS

USD

Glaukos Corporation Common Stock

$87.610+3.020 (3.570%)

实时价格

Healthcare
医疗设备
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$84.590

最高价

$89.620

最低价

$84.381

成交量

0.33M

公司基本面

市值

5.0B

所属行业

医疗设备

国家/地区

United States

交易统计

平均成交量

1.10M

交易所

NYQ

货币

USD

52周价格范围

最低价 $77.102当前价 $87.610最高价 $163.71

AI分析报告

最后更新: 2025年5月4日
由AI生成数据来源: Yahoo Finance, Bloomberg, SEC

GKOS: Glaukos Corporation Common Stock - What's Happening and What to Watch

Stock Symbol: GKOS Generate Date: 2025-05-04 23:22:14

Alright, let's break down what's been going on with Glaukos (GKOS) and what the recent information might suggest. Think of this as looking at the puzzle pieces to get a clearer picture.

The Buzz from Recent News

Looking at the news headlines from the past couple of weeks, there's a clear theme: analysts are cutting their price targets for GKOS. We saw Stephens & Co., Stifel, Truist Securities, Needham, Mizuho, and Piper Sandler all lower where they think the stock price is headed. That's a bunch of folks on Wall Street saying, "Okay, maybe it's not going quite as high as we thought before."

Now, here's the interesting part: even though they lowered their targets, most of these analysts still kept a positive rating on the stock – things like "Overweight," "Buy," or "Outperform." It's like they're saying, "We still like the company, but we're being a bit more realistic about the near-term price." The big exception was Wells Fargo, which actually downgraded the stock from "Overweight" to "Equal-Weight" and gave it a much lower price target of $86.

Right in the middle of all these analyst updates (on April 30th), Glaukos announced its First Quarter 2025 financial results. This is a big deal and almost certainly the reason analysts were busy changing their numbers. The details of those results aren't in the news snippets here, but the analyst reactions tell us they likely weren't quite as strong as some might have hoped, leading to those lower price targets.

So, the news vibe is a bit mixed. It's not all doom and gloom since most analysts still see potential, but the lower price targets and one downgrade show some clear caution after the latest earnings report. Interestingly, the AI sentiment score provided is quite high, which might be picking up on the fact that most ratings remained positive despite the target cuts.

Checking the Price Chart

Now, let's look at what the stock price itself has been doing over the last few months. If you glance at the historical data, GKOS was trading up around $150-$160 back in early February. Then, around February 21st, something big happened – the price took a massive dive, dropping significantly on really high trading volume. It's been a tough ride since then.

The stock continued to fall through March and into April, bouncing around in a much lower range, mostly between $80 and $100. The last couple of trading days (May 1st and 2nd) saw more volatility and high volume, with the price dipping and then recovering slightly. The previous day's close was $83.54.

Compared to where it was just a few months ago, the stock has taken a serious hit. It's currently trading very close to its 52-week low of $77.102.

The AI prediction for the next couple of days is pretty modest, suggesting a small upward move (around +1.95% tomorrow, +2.32% the day after). It predicts no change for today. This suggests the AI sees a bit of stabilization or a slight bounce from these lower levels in the very near term.

Putting It All Together: What Might This Mean?

Okay, let's connect the dots. The stock price has fallen dramatically, likely reflecting concerns that surfaced around late February and were perhaps confirmed or amplified by the recent Q1 results. Analysts responded by lowering their expectations for the stock's price, though many still believe in the company long-term, keeping their "Buy" or "Overweight" ratings.

Given the steep drop and the fact that the current price is near the 52-week low and below most of the new analyst price targets (which range from $86 to $175, with many around $115-$135), the situation looks like one where the stock has been heavily beaten down.

The AI's prediction for small positive moves in the next couple of days, combined with the AI recommendation data calling it an "Undervalued Gem" with a moderate confidence score, might suggest that the AI sees the current price as potentially attractive after the big fall.

So, what's the apparent near-term leaning? It seems to lean towards a "watch and see" or potentially an "accumulation zone" for investors willing to take on some risk, rather than a strong "sell" signal at these levels. The big drop has already happened, and the price is now significantly below where most analysts think it should eventually trade, even with their lowered targets.

Potential Strategy Ideas (Just things to consider, not advice!):

  • Potential Entry Consideration: If you're thinking about this stock, the current price area (around the previous close of $83.54) is near the 52-week low. The AI recommendation data suggested entry points slightly higher ($88.16, $89.68), but being below those might look interesting to some. One might consider if the stock holds above its 52-week low ($77.102) as a sign of potential stabilization.
  • Potential Exit/Stop-Loss Consideration: To manage risk if the price keeps falling, a stop-loss order could be placed below the 52-week low of $77.102, or perhaps slightly below the recommended stop-loss level of $78.84. If the stock does start to recover, the recommended take-profit level of $96.51 could be a first area to watch for potentially selling some shares. Another potential area to watch for resistance (where the price might struggle to go higher) could be around the $100-$105 level, where it traded briefly in March before falling further.

A Little About Glaukos

Remember, Glaukos is a medical technology company focused on eye health treatments. They make devices and therapies for conditions like glaucoma. This means their business success depends on things like getting their products approved, how well doctors adopt them, and overall healthcare trends. The recent Q1 results and analyst reactions are likely tied directly to how their products are selling and what the outlook is for new treatments they're developing.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are risky, and prices can go down as well as up. You should always do your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

相关新闻

Analyst Upgrades

Stephens & Co. Maintains Overweight on Glaukos, Lowers Price Target to $115

Stephens & Co. analyst Mason Carrico maintains Glaukos with a Overweight and lowers the price target from $140 to $115.

查看更多
Stephens & Co. Maintains Overweight on Glaukos, Lowers Price Target to $115
Analyst Upgrades

Stifel Maintains Buy on Glaukos, Lowers Price Target to $115

Stifel analyst Thomas Stephan maintains Glaukos with a Buy and lowers the price target from $140 to $115.

查看更多
Stifel Maintains Buy on Glaukos, Lowers Price Target to $115
Analyst Upgrades

Truist Securities Reiterates Buy on Glaukos, Lowers Price Target to $135

Truist Securities analyst Richard Newitter reiterates Glaukos with a Buy and lowers the price target from $140 to $135.

查看更多
Truist Securities Reiterates Buy on Glaukos, Lowers Price Target to $135
Analyst Upgrades

Wells Fargo Downgrades Glaukos to Equal-Weight, Lowers Price Target to $86

Wells Fargo analyst Larry Biegelsen downgrades Glaukos from Overweight to Equal-Weight and lowers the price target from $160 to $86.

查看更多
Wells Fargo Downgrades Glaukos to Equal-Weight, Lowers Price Target to $86
Analyst Upgrades

Needham Maintains Buy on Glaukos, Lowers Price Target to $115

Needham analyst David Saxon maintains Glaukos with a Buy and lowers the price target from $176 to $115.

查看更多
Needham Maintains Buy on Glaukos, Lowers Price Target to $115
BusinessWire

Glaukos Announces First Quarter 2025 Financial Results

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial

Analyst Upgrades

Mizuho Maintains Outperform on Glaukos, Lowers Price Target to $175

Mizuho analyst Anthony Petrone maintains Glaukos with a Outperform and lowers the price target from $200 to $175.

AI预测Beta

AI建议

看涨

更新于: 2025年5月4日 21:03

看跌中性看涨

62.1% 置信度

风险与交易

风险等级3/5
中风险
适合于
价值增长
交易指南

入场点

$88.16

止盈点

$96.51

止损点

$78.84

关键因素

DMI显示看跌趋势(ADX:21.6,+DI:16.5,-DI:17.9),表明需谨慎
当前价格非常接近支撑水平$87.93,表明有强烈的买入机会
交易量是平均值的14.4倍(12,740),表明极强的买入压力
MACD -0.2223低于信号线-0.1066,表明看跌交叉

保持更新

设置价格提醒,获取AI分析更新和实时市场新闻。